Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) should not be taken during pregnancy. The medicine is not licensed for use in pregnancy, and UK clinical guidance is clear: if you become pregnant while on Mounjaro, stop treatment and contact your GP or midwife promptly. The licensed Patient Information Leaflet and NHS guidance on tirzepatide both advise against its use during pregnancy, while breastfeeding, or when actively trying to conceive. This page sets out what the evidence says, what is still uncertain, and who to speak to if your situation is changing.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The clearest starting point is the official position. The Mounjaro Summary of Product Characteristics, cross-referenced by the NHS tirzepatide medicines page, states that tirzepatide should not be used during pregnancy. It recommends that women of childbearing potential use effective contraception while on treatment. That position is not a precautionary footnote buried in small print; it reflects a genuine gap in human safety data and findings from animal reproductive studies.
Animal studies identified embryo-foetal toxicity at exposures comparable to those seen in humans at therapeutic doses. Because those findings exist, and because there are no controlled human trials in pregnant women (nor would it be ethical to conduct them), the licensed position is unambiguous: the risk-to-benefit calculation does not support use in pregnancy.
If you discover you are pregnant while taking Mounjaro, the advice is to stop treatment and contact your GP or midwife without delay. You can also contact our aftercare team, who are available seven days a week and can advise on next steps through your prescriber.
This is a question our prescribers hear regularly, and it is worth addressing directly. There is no clinical evidence that Mounjaro causes infertility. Some women report that weight loss on GLP-1 medicines coincides with a return or regularisation of their menstrual cycle, particularly in conditions such as polycystic ovary syndrome where excess weight can suppress ovulation. That means it is possible to become pregnant on Mounjaro, including for women who had previously found it difficult to conceive. That possibility underlines why reliable contraception matters from day one of treatment.
The NHS England guidance on weight management injections addresses this explicitly. If you are using the contraceptive pill, you need to add a barrier method (such as condoms) for the first four weeks of starting Mounjaro and for four weeks after every dose increase. Tirzepatide slows gastric emptying, and that delay can reduce how much of an oral medicine is absorbed at the right time. There is no equivalent documented interaction for semaglutide, but the tirzepatide guidance is firm. Our page on who cannot take Mounjaro covers the full list of contraindications and cautions in more detail.
If you are thinking about starting a family in the coming months, the right time to plan is before conception, not after a positive test. The MHRA advises using contraception while on GLP-1 medicines and for an appropriate wash-out period before trying to conceive. The exact length of that period should be agreed with your prescriber; it is not a figure to guess at, because the clinical picture (your dose, your duration of treatment, any underlying conditions) shapes the answer.
Stopping treatment does not mean your progress disappears. Weight loss achieved with Mounjaro tends to be sustained for a period after stopping, and your prescriber can discuss what a sensible plan looks like for your circumstances. The general eligibility and suitability page gives a broader overview of who Mounjaro is and is not suitable for. For questions about other medicines or supplements during treatment, you may also find our pages on taking Mounjaro alongside sertraline or creatine use on tirzepatide useful reference points.
Timing matters in a practical sense too. If you are already on treatment and a planned pregnancy is on the horizon (perhaps earlier than expected) do not wait until your next monthly order to raise the question. Contact your prescriber now. Our clinical team reviews patient questions seven days a week, so there is never a reason to sit on a concern until the calendar lines up.
On a situation like this, a content page takes you only so far. The right people are your GP, your midwife if you are already pregnant, and your prescriber. Together they can look at your whole picture: underlying conditions, any fertility investigations you have had, current contraception, and your timeline.
If you are currently taking Mounjaro through nume and your circumstances have changed (a positive pregnancy test, plans to start trying, or concerns about your contraceptive coverage) please reach out through our support line so your prescriber can review your treatment promptly. If you have not yet started treatment and want to understand your options, including conditions that may affect suitability, you can read more on our Mounjaro treatment page or check the BMI and eligibility guide for the licensing criteria. For side effects during treatment, including GI symptoms sometimes confused with early pregnancy, our page on managing nausea on Mounjaro covers what is safe to take alongside it.
Mounjaro is a Prescription Only Medicine. Every decision about starting, continuing or stopping it is made by a GPhC-registered Independent Prescriber, a real clinician who reads your full clinical picture, not a checklist. That clinical oversight is the point. If you are ready to explore weight management treatment and your situation is stable, a free consultation with our prescribers is the right next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.